Bicara Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2023
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Selling, General & Admin	29.13	18.77	9.27	6.34
Research & Development	111.99	63.62	30.62	31.31
Total Operating Expenses	141.12	82.39	39.89	37.66
Operating Income	-141.12	-82.39	-39.89	-37.66
Interest Income	19.95	14.58	1.31	0
Interest Expense	-	-	-	-0.11
Other Non-Operating Income (Expense)	-	-	-13.41	-0.08
Total Non-Operating Income (Expense)	19.95	14.58	-12.09	-0.19
Pretax Income	-121.17	-67.81	-51.98	-37.84
Provision for Income Taxes	0.35	0.19	0.01	0
Net Income	-121.52	-68	-51.99	-37.85
Net Income to Common	-121.52	-68	-51.99	-37.85
Shares Outstanding (Basic)	54	17	1	0
Shares Outstanding (Diluted)	54	17	1	0
Shares Change (YoY)	1565.34%	2796.96%	35.20%	-
EPS (Basic)	-2.24	-4.05	-89.61	-88.20
EPS (Diluted)	-2.24	-4.05	-89.61	-88.20
Free Cash Flow	-113.06	-74.82	-46.21	-32.27
Free Cash Flow Per Share	-2.07	-4.45	-79.66	-75.20
EBITDA	-141.04	-82.33	-39.87	-37.65
EBIT	-141.12	-82.39	-39.89	-37.66
Effective Tax Rate	-0.29%	-0.28%	-0.01%	-0.00%

Updated Nov 10, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q